Background: More than 60% children with small bowel transplantation (SBTx) experience acute cellular rejection.
Purpose/methods: To identify children at risk of rejection, donor- and third-party-induced proliferation of T-helper and T cytotoxic (Tc) cells, and their naïve and memory (M) subsets was evaluated simultaneously in single blood samples from 28 children who received SBTx after induction with rabbit anti-human thymocyte globulin. Proliferation was measured by dilution of the intravital dye carboxyfluorescein succinimidyl ester (CFSE) in 3- to 4-day mixed leukocyte reaction co-culture. The ratio of donor- and third-party-induced proliferation (CFSE(low)) of the T cells was reported as the immunoreactivity (IR) index for each subset. Rejectors were defined as those who experienced biopsy-proven acute cellular rejection within 60 days of the assay. IR more than 1 signified increased risk of rejection and IR less than 1 implied decreased risk.
Results: Rejectors (n=16) and Nonrejectors (n=12) were similar in general demographics. Significantly higher counts were observed for all proliferated CFSE(low) T-cell subsets among rejectors, compared with nonrejectors. Logistic regression, leave-one-out cross-validation, and receiver operating characteristic analyses showed that the IR of Tc associated best with biopsy-proven rejection (sensitivity >87.5%, specificity >83.3%). IR of CFSE(low) Tc correlated significantly with IR of proinflammatory, allospecific CD154(+)Tc-M (r=0.682, P=0.005) and inversely with IR of allospecific, antiinflammatory, CTLA4(+)Tc-M (r=-0.638, P=0.047).
Conclusions: Proliferative alloresponses of Tc cells can identify rejection-prone children receiving SBTx.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/TP.0b013e3181d98c0f | DOI Listing |
Proc Natl Acad Sci U S A
January 2025
Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN 47405.
Dysregulation of GABAergic inhibition is associated with pathological pain. Consequently, enhancement of GABAergic transmission represents a potential analgesic strategy. However, therapeutic potential of current GABA agonists and modulators is limited by unwanted side effects.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
January 2025
Laboratory of Precision Medicine and Biopharmaceuticals, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Recurrent missense mutations in the human epidermal growth factor receptor 2 (HER2) have been identified across various human cancers. Among these mutations, the active S310F mutation in the HER2 extracellular domain stands out as not only oncogenic but also confers resistance to pertuzumab, an antibody drug widely used in clinical cancer therapy, by impeding its binding. In this study, we have successfully employed computational-aided rational design to undertake directed evolution of pertuzumab, resulting in the creation of an evolved pertuzumab variant named Ptz-SA.
View Article and Find Full Text PDFNatural killer (NK) cells have proven to be safe and effective immunotherapies, associated with favorable treatment responses in chronic myeloid leukemia (CML). Augmenting NK cell function with oncological drugs could improve NK cell-based immunotherapies. Here, we used a high-throughput drug screen consisting of over 500 small-molecule compounds to systematically evaluate the effects of oncological drugs on primary NK cells against CML cells.
View Article and Find Full Text PDFACS Infect Dis
January 2025
Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, United States.
Developing new classes of drugs that are active against infections caused by is a priority for treating and managing this deadly disease. Here, we describe screening a small library of 20 DNA gyrase inhibitors and identifying new lead compounds. Three structurally diverse analogues were identified with minimal inhibitory concentrations of 0.
View Article and Find Full Text PDFAdv Sci (Weinh)
January 2025
ETH Zurich, Department of Biosystems Science and Engineering, Klingelbergstrasse 48, Basel, CH-4056, Switzerland.
Neo-vascularization plays a key role in achieving long-term viability of engineered cells contained in medical implants used in precision medicine. Moreover, strategies to promote neo-vascularization around medical implants may also be useful to promote the healing of deep wounds. In this context, a biocompatible, electroconductive borophene-poly(ε-caprolactone) (PCL) 3D platform is developed, which is called VOLT, to support designer cells engineered with a direct-current (DC) voltage-controlled gene circuit that drives secretion of vascular endothelial growth factor A (VEGFA).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!